Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02303262 · ClinicalTrials.gov registry record · Phase 2

SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma

A Phase 2 study of Metastatic Leiomyosarcoma, sponsored by Sarcoma Alliance for Research through Collaboration.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target
5
Study locations

NCT02303262 is a Phase 2 study of Metastatic Leiomyosarcoma that has completed, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 20 participants, below the 51-participant average among 4 other Metastatic Leiomyosarcoma trials with a reported enrollment target (61% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02303262, a Phase 2 study of Metastatic Leiomyosarcoma, has completed, sponsored by Sarcoma Alliance for Research through Collaboration.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target
5
Study locations

Study Summary

This is an open-label, multi-center, Phase II trial studying the combination of mocetinostat and gemcitabine in patients who have previously demonstrated disease progression either while, or within six months after, receiving chemotherapy with a gemcitabine-based regimen.

Conditions Studied

Metastatic Leiomyosarcoma

Interventions

  • DRUG Gemcitabine
  • DRUG Mocetinostat

Study Locations (5)

Massachusetts

  • Massachusetts General Hospital/Dana Farber Cancer Institute - Boston

Michigan

  • University of Michigan - Ann Arbor

New York

  • Memorial Sloan Kettering Cancer Center - New York

Ohio

  • Ohio State University - Columbus

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2015-11-12
Est. Completion 2016-12
Phase Phase 2

Sponsor

Sarcoma Alliance for Research through Collaboration

20 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02303262

The ClinicalTrials.gov registry entry for NCT02303262 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 51-participant average among 4 other Metastatic Leiomyosarcoma trials with a reported enrollment target (61% lower). The listed sponsor is Sarcoma Alliance for Research through Collaboration, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Leiomyosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Gemcitabine is the first listed.

NCT02303262 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, Michigan, New York.

Frequently Asked Questions

What is clinical trial NCT02303262 about?

NCT02303262 is a clinical study titled "SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma". This is an open-label, multi-center, Phase II trial studying the combination of mocetinostat and gemcitabine in patients who have previously demonstrated disease progression either while, or within six months after, receiving chemotherapy with a gemcitabine-based regimen.

What is the current status of trial NCT02303262?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2015-11-12. Estimated completion is 2016-12.

What conditions does trial NCT02303262 study?

This clinical trial studies the following conditions: Metastatic Leiomyosarcoma.

What interventions are being tested in trial NCT02303262?

The interventions under investigation include: Gemcitabine (DRUG), Mocetinostat (DRUG).

Who is sponsoring clinical trial NCT02303262?

This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02303262 being conducted?

This trial has 5 study locations across Massachusetts, Michigan, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Leiomyosarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Leiomyosarcoma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.